Kadali K, Nierobisch N, Maibach F, Heesen P, Alcaide-Leon P, Hullner M
Sci Rep. 2025; 15(1):7749.
PMID: 40044711
PMC: 11882894.
DOI: 10.1038/s41598-025-90472-8.
Wagle N, Sharma A, Nguyen M, Truong J, Juarez T, Kesari S
Neurooncol Adv. 2024; 6(1):vdae110.
PMID: 39036436
PMC: 11259949.
DOI: 10.1093/noajnl/vdae110.
Ziegenfeuter J, Delbridge C, Bernhardt D, Gempt J, Schmidt-Graf F, Hedderich D
Eur J Nucl Med Mol Imaging. 2024; 51(12):3685-3695.
PMID: 38837060
PMC: 11445274.
DOI: 10.1007/s00259-024-06782-y.
Dai L, Jing Z, Zhu Y, Deng K, Ma L
Am J Cancer Res. 2024; 13(12):5950-5965.
PMID: 38187045
PMC: 10767359.
Huo X, Wang Y, Ma S, Zhu S, Wang K, Ji Q
Medicine (Baltimore). 2023; 102(51):e36581.
PMID: 38134061
PMC: 10735121.
DOI: 10.1097/MD.0000000000036581.
Apparent Diffusion Coefficient Metrics to Differentiate between Treatment-Related Abnormalities and Tumor Progression in Post-Treatment Glioblastoma Patients: A Retrospective Study.
van den Elshout R, Herings S, Mannil M, Gijtenbeek A, Laan M, Smeenk R
Cancers (Basel). 2023; 15(20).
PMID: 37894355
PMC: 10605800.
DOI: 10.3390/cancers15204990.
The value of arterial spin labelling (ASL) perfusion MRI in the assessment of post-treatment progression in adult glioma: A systematic review and meta-analysis.
Alsulami T, Hyare H, Thomas D, Golay X
Neurooncol Adv. 2023; 5(1):vdad122.
PMID: 37841694
PMC: 10576519.
DOI: 10.1093/noajnl/vdad122.
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
Wen P, van den Bent M, Youssef G, Cloughesy T, Ellingson B, Weller M
J Clin Oncol. 2023; 41(33):5187-5199.
PMID: 37774317
PMC: 10860967.
DOI: 10.1200/JCO.23.01059.
Recapitulating the Key Advances in the Diagnosis and Prognosis of High-Grade Gliomas: Second Half of 2021 Update.
Frosina G
Int J Mol Sci. 2023; 24(7).
PMID: 37047356
PMC: 10094646.
DOI: 10.3390/ijms24076375.
Highlighted Advances in Therapies for Difficult-To-Treat Brain Tumours Such as Glioblastoma.
Cruz N, Herculano-Carvalho M, Roque D, Faria C, Cascao R, Ferreira H
Pharmaceutics. 2023; 15(3).
PMID: 36986790
PMC: 10054750.
DOI: 10.3390/pharmaceutics15030928.
Dialog beyond the Grave: Necrosis in the Tumor Microenvironment and Its Contribution to Tumor Growth.
Zapletal E, Vasiljevic T, Busson P, Glavan T
Int J Mol Sci. 2023; 24(6).
PMID: 36982351
PMC: 10049335.
DOI: 10.3390/ijms24065278.
Effects of glioblastoma-derived extracellular vesicles on the functions of immune cells.
Musatova O, Rubtsov Y
Front Cell Dev Biol. 2023; 11:1060000.
PMID: 36960410
PMC: 10028257.
DOI: 10.3389/fcell.2023.1060000.
T1-Weighted Contrast Enhancement, Apparent Diffusion Coefficient, and Cerebral-Blood-Volume Changes after Glioblastoma Resection: MRI within 48 Hours vs. beyond 48 Hours.
Negroni D, Bono R, Soligo E, Longo V, Cossandi C, Carriero A
Tomography. 2023; 9(1):342-351.
PMID: 36828379
PMC: 9967426.
DOI: 10.3390/tomography9010027.
Undesired impact of iron supplement on MRI assessment of post-treatment glioblastoma.
Park D, Lobbous M, Nabors L, Markert J, Kim J
CNS Oncol. 2022; 11(4):CNS90.
PMID: 36408899
PMC: 9830595.
DOI: 10.2217/cns-2021-0018.
Diffusion imaging could aid to differentiate between glioma progression and treatment-related abnormalities: a meta-analysis.
van den Elshout R, Scheenen T, Driessen C, Smeenk R, Meijer F, Henssen D
Insights Imaging. 2022; 13(1):158.
PMID: 36194373
PMC: 9532499.
DOI: 10.1186/s13244-022-01295-4.
Tumor Progression and Treatment-Related Changes: Radiological Diagnosis Challenges for the Evaluation of Post Treated Glioma.
Qin D, Yang G, Jing H, Tan Y, Zhao B, Zhang H
Cancers (Basel). 2022; 14(15).
PMID: 35954435
PMC: 9367286.
DOI: 10.3390/cancers14153771.
Applications of Radiomics and Radiogenomics in High-Grade Gliomas in the Era of Precision Medicine.
Kazerooni A, Bagley S, Akbari H, Saxena S, Bagheri S, Guo J
Cancers (Basel). 2021; 13(23).
PMID: 34885031
PMC: 8656630.
DOI: 10.3390/cancers13235921.
Current emerging MRI tools for radionecrosis and pseudoprogression diagnosis.
Nichelli L, Casagranda S
Curr Opin Oncol. 2021; 33(6):597-607.
PMID: 34534142
PMC: 8528135.
DOI: 10.1097/CCO.0000000000000793.
Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological, and Molecular Features.
Li M, Ren X, Dong G, Wang J, Jiang H, Yang C
Front Oncol. 2021; 11:627325.
PMID: 33959496
PMC: 8093388.
DOI: 10.3389/fonc.2021.627325.